Thus, IL-8 plays a critical role in ICC progression through prometastatic CD97, which indicates that small inhibitors targeting the tumor microenvironment may serve as potential candidates for the treatment of ICC (summarized in Fig. 6). The gene discussed is CXCL8; the disease is neoplasm.